BONE MARROW TRANSPLANTATION PROGRAM Nelson Chao, M.D. and Joanne Kurtzberg, M.D., Co-Leaders It is the broad, long-term goal of this program to build on and extend the current knowledge in the field oi bone marrow transplantation. This program is a multidisciplinary clinical, basic and translational research effort whose overall goal is to improve outcomes for patients with solid and liquid malignancies utilizing hematopoietic stem cells for hematopoietie rescue and immunomodulation. To this end, the investigators of this application will utilize the approach of translational research, bridging the novel experimental concepts and observations made at the laboratory bench to clinical application at the patients'bedside. In both basic and clinical areas, the Bone Marrow Transplantation Program fosters interactions between many Programs and members of the Comprehensive Cancer Center.
The aims of the Program are: (1) to optimize the use of allogeneic and autologous transplantation of hematopoietic stem cells in the treatment of patients with malignancies; (2) to use and compare various alternative sources of hematopoietic stem cells for allogeneic transplantation; (3) to develop novel preparatory regimens for allogeneic stem cell transplantation; (4) to understand the basic biology of graft versus tumor (GvT) and to explore new ways to induce GvT effects following transplantation; (5) to study the nature of and define the problems associated with hematopoietic and immunologic reconstitution after allogeneic transplantation with the overall goal of developing novel supportive care measures for patients transplanted with stem cells from alternative and mismatched donors; (6) to understand hematopoietic stem cell development and control of differentiation; (7) to develop targeted chemotherapy dosing based on patient's pharmacogenomics information.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014236-35
Application #
7764694
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-01-01
Budget End
2009-12-31
Support Year
35
Fiscal Year
2009
Total Cost
$44,962
Indirect Cost
Name
Duke University
Department
Type
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Xu, Yinghui; Wang, Yanru; Liu, Hongliang et al. (2018) Genetic variants in the metzincin metallopeptidase family genes predict melanoma survival. Mol Carcinog 57:22-31
Abdi, Khadar; Kuo, Chay T (2018) Laminating the mammalian cortex during development: cell polarity protein function and Hippo signaling. Genes Dev 32:740-741
Lu, Min; Sanderson, Sydney M; Zessin, Amelia et al. (2018) Exercise inhibits tumor growth and central carbon metabolism in patient-derived xenograft models of colorectal cancer. Cancer Metab 6:14
Qian, Danwen; Liu, Hongliang; Wang, Xiaomeng et al. (2018) Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. Int J Cancer :
Ashcraft, Kathleen A; Choudhury, Kingshuk Roy; Birer, Sam R et al. (2018) Application of a Novel Murine Ear Vein Model to Evaluate the Effects of a Vascular Radioprotectant on Radiation-Induced Vascular Permeability and Leukocyte Adhesion. Radiat Res 190:12-21
Ong, Cecilia T; Campbell, Brittany M; Thomas, Samantha M et al. (2018) Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. Ann Surg Oncol 25:2249-2260
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408

Showing the most recent 10 out of 513 publications